Avastin (bevacizumab) is not technically a last resort for glioblastoma, but it is typically reserved for recurrent disease, meaning it enters the picture after the standard first-line treatment has stopped working. The FDA approved it in 2009 specifically for glioblastoma that has progressed after prior therapy. So while it’s not the final option available, it does sit later in the treatment sequence, and for many patients it represents one of the few remaining proven tools when the cancer comes back.
Where Avastin Fits in the Treatment Sequence
The standard first-line treatment for glioblastoma follows what’s known as the Stupp regimen: surgery to remove as much tumor as possible, followed by radiation combined with daily chemotherapy (temozolomide), then additional cycles of temozolomide on its own. This is the starting point for nearly all glioblastoma patients, and Avastin plays no role at this stage.
When the tumor eventually grows back, which it almost always does, oncologists shift to second-line treatments. This is where Avastin comes in. Based on data from the BRAIN clinical trial, the FDA granted it accelerated approval as a single agent for patients whose glioblastoma had progressed despite prior therapy. It works by blocking a protein that tumors use to build new blood vessels, essentially cutting off part of the tumor’s supply line. While some oncologists do use it alongside first-line treatment, that approach hasn’t shown a clear survival benefit in large trials, so the standard practice remains using it at recurrence.
What Avastin Does and Doesn’t Do for Survival
Avastin is not a cure, and it’s important to set realistic expectations. In patients who had already failed both radiation and chemotherapy, the median progression-free survival on Avastin was 3.5 months, and the median overall survival was 7.5 months. About one in five patients (21.5%) reached six months without their tumor growing further, and roughly 11.5% were alive at one year.
Those numbers may sound modest, but they vary significantly depending on how a patient’s tumor responds. Patients whose tumors visibly shrank on imaging had a median progression-free survival of 5.4 months compared to just 1.9 months for non-responders. Their one-year survival rate was 21.3%, while none of the non-responders survived to that point. So the drug clearly helps some patients more than others, and early imaging after starting treatment gives a strong signal about which group you fall into.
Quality of Life Improvements
Where Avastin arguably makes its strongest case is in how patients feel during those extra months. One of the most debilitating aspects of glioblastoma is brain swelling, which worsens neurological symptoms and forces patients onto high doses of steroids. Those steroids carry their own brutal side effects: muscle weakness, weight gain, mood changes, insomnia, and immune suppression.
Avastin has a potent anti-swelling effect in the brain. In the BRAIN study, about half of patients were on steroids when they started Avastin. Roughly 30% to 47% of those patients achieved a sustained steroid dose reduction of at least 50%, and 16% to 21% were able to stop steroids entirely for a significant portion of their treatment. A separate study found that within two months of starting Avastin, the median steroid dose dropped from 6 mg to just 0.4 mg, while patients not on Avastin saw their steroid dose climb from 4 mg to 8 mg over the same period.
This steroid reduction translated into real functional gains. Patients on Avastin scored nearly double on measures of independent living compared to those not receiving it (15.0 versus 8.2). They retained the ability to care for themselves, move around, and engage with family. The survival time gained with Avastin wasn’t just more time in a hospital bed. It was largely time spent with preserved independence, which matters enormously to patients and families navigating this disease.
Risks to Be Aware Of
Avastin carries some serious potential complications. The most clinically significant is an increased risk of blood clots (thromboembolism), which occurred in about 4% of glioblastoma patients in pooled analyses. Less common but possible complications include bleeding within the brain, gastrointestinal perforation, heart dysfunction, and kidney problems. High blood pressure and fatigue are more routine side effects. For most patients with recurrent glioblastoma, the potential benefits in symptom control and quality of life outweigh these risks, but this is a conversation worth having with your oncologist based on your specific health profile.
What Happens When Avastin Stops Working
If the tumor progresses on Avastin, the situation becomes more challenging, but options still exist. In one review of 174 patients whose glioblastoma progressed on Avastin, about half (49%) went on to receive additional treatment. Those treatments split roughly evenly between continuing Avastin in a new combination and switching to a completely different approach. Among both groups, about half received different chemotherapy drugs, over a quarter enrolled in clinical trials, and a smaller number had additional radiation.
Clinical trials are a particularly important option at this stage. Many trials for recurrent glioblastoma are specifically designed for patients who haven’t yet received Avastin, which is worth knowing if you’re weighing when to start it. Once you’ve been on Avastin, the pool of eligible trials may narrow. This is one reason some oncologists discuss the timing of Avastin carefully with patients, balancing its clear quality-of-life benefits against the desire to keep clinical trial doors open.
Not the Last Option, but a Late-Stage One
Calling Avastin a “last resort” oversimplifies things. It’s a second-line treatment with a specific FDA indication for recurrent disease, and roughly half of patients who progress on it still go on to receive further therapy. At the same time, it does occupy a later position in the treatment playbook, and the options after it are limited and less well-proven. Its greatest value may not be in extending life by months, but in making the time a patient has more livable: less swelling, fewer steroids, more independence. For a disease with a five-year survival rate in the single digits, that counts for a great deal.